Bruker introduces novel NMR solutions at ENC 2017
New magnetic resonance technologies and applications open new frontiers for biological, chemical and materials research and routine analysis in pharmaceutical and chemical industries.
At the 58th Experimental Nuclear Magnetic Resonance Conference, Bruker announced new software and hardware addressing the need for enhanced workflow solutions for NMR spectroscopy research and analysis. These solutions will benefit researchers in many disciplines of NMR, while providing productivity enhancements for pharmaceutical users.
Rainer Kuemmerle, NMR Product Manager for the Bruker BioSpin Magnetic Resonance Spectroscopy division, explained: “We always have our customers in mind when developing new technologies and applications, and these latest NMR solutions exemplify this mindset. From academic, to pharma, and to chemical and advanced materials customers, we focus on making our customers successful by enhancing their productivity and expanding their range of NMR applications.”
New Software
TopSpin 4 is the next generation of Bruker’s NMR software for spectrometer control and data analysis, designed for the newly introduced AVANCE NEO platform. The combination of a new user interface and capabilities to support multiple receivers and other AVANCE NEO capabilities, will make TopSpin 4 a very powerful and intuitive software for NMR spectroscopists. Existing AVANCE III HD customers will also benefit from a new TopSpin 3.5 version, as we continue enhancements and support for the Avance III HD platform.
Designed to simplify and accelerate the setup of biomolecular NMR experiments, the new bioTop module performs most biomolecular tasks in full automation. Only minimal user interaction is required for most experiments. The process starts after inserting the sample, taking care of shimming, locking and tuning if necessary. From experiment selections to final processed spectra, including optimization of commonly used parameters, bioTop can be customized to accommodate much of the workflow in biomolecular NMR laboratories.
The new TopSolids module is an intuitive, workflow-based software for solid-state NMR. TopSolids is designed to give easy access to the delicate setup of probe hardware and complex solid-state NMR experiments, e.g. from structural biology on membrane proteins, to pharmaceutical comounds, to catalysis, battery research, polymer or material science work. For any customer who could benefit from solid-state NMR, TopSolids 2.0 will be a great productivity tool, decreasing the time for setup and providing even more results, for novice and expert users.
Of particular interest to biotech and pharma customers are two novel solutions:
For NMR detection, Bruker is pleased to introduce the new iProbe platform. This novel NMR probe architecture allows not only for an increase in signal to noise, and faster and more accurate rf tuning, but also provides a more flexible design that allows easier customization of NMR probes for dedicated applications. The first probes introduced on this platform include the industry-leading SmartProbe iProbes, available now from 400-600 MHz, offering up to 10% increase in sensitivity.
The InsightMR portfolio of applications for monitoring chemical and biological processes is expanding further, to increase understanding of reaction mechanisms, chemical processes as well as cell metabolism. InsightXpress now enhances the NMR monitoring of fast reactions and rapid, automated, screening of reactions conditions. For studies on living cells, InsightCell now monitors living cells to study their biological activity through direct NMR measurements of variations in metabolite concentration.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.